ArticleBMJ oncology2026
Sex differences in the cancer proteome.
Article in BMJ oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex Differences in Cancer Functional Genomics: Gene Dependency and Drug Sensitivity.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Objectives: Proteins play a central role in cancer biology. They are the most common drug targets and biomarkers. Sex influences the proteome in many diseases ranging from neurological to cardiovascular. In cancer, sex is associated with incidence, progression and therapeutic response, as well as characteristics of the tumour genome and transcriptome. This study aimed to characterise the extent to which sex differences impact the cancer proteome. Design: Retrospective analysis of publicly available proteogenomic datasets. Setting: Clinical Proteomic Tumor Analysis Consortium cancer cohorts. Participants: A total of 1590 proteomes from eight cancer types. Interventions: Not applicable. Main outcome measures: Sex-differential protein abundance and its association with copy number aberrations, biological pathways and gene dependency. Results: We identified 901 genes with sex-differential protein abundance in adenocarcinomas of the lung and 20 genes across five other tumour types: squamous cell carcinoma of the lung, hepatocellular carcinomas, clear cell cancers of the kidney, adenocarcinomas of the pancreas and glioblastoma. A subset of these protein differences could be rationalised by sex-differential copy number aberrations. Pathway analysis showed that male-biased proteins in lung adenocarcinoma were enriched in MYC and E2F target pathways, and female-biased proteins were enriched in metabolic and stress-response pathways. These genes also exhibited stronger CRISPR gene dependency in cell lines derived from lung adenocarcinoma. Conclusions: These findings highlight the modest impact of sex on the cancer proteome, but the very limited power of existing proteomics cohorts for these analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.